MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms
Pharmacologic targeting of murine double minute 2 (MDM2) represents one of the most compelling strategies for therapeutic reactivation of wild-type p53 in hematologic malignancies.
Pharmacologic targeting of murine double minute 2 (MDM2) represents one of the most compelling strategies for therapeutic reactivation of wild-type p53 in hematologic malignancies.
The review focuses on MDM2 inhibition as a promising therapeutic strategy to reactivate p53 in myeloid diseases, particularly AML and myeloproliferative neoplasms, highlighting clinical experiences, resistance mechanisms, and future directions.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Management of Acute Myeloid Leukemia: A Review
- Old cells, new tricks—important clue to AML diagnosis and cure discovered
- Treatment of Acute Myeloid Leukaemia
- Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates
- Research blog: Accelerating progress in AML